SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
Valuation | |
---|---|
Market Cap ($M) | 10,974.37 |
Enterprise Value ($M) | 9,898.27 |
Book Value ($M) | 2,589.70 |
Book Value / Share | 25.97 |
Price / Book | 4.24 |
NCAV ($M) | 595.70 |
NCAV / Share | 5.97 |
Price / NCAV | 18.42 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | 0.11 |
Return on Assets (ROA) | 0.10 |
Return on Equity (ROE) | 0.15 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 3.28 |
Current Ratio | 3.40 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 1,724.70 |
Assets | 3,718.70 |
Liabilities | 1,129.00 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 2,355.30 |
Operating Income | 583.00 |
Net Income | 341.30 |
Earnings Per Share Basic And Diluted | n/a |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 595.40 |
Cash from Investing | -126.80 |
Cash from Financing | -486.70 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Vanguard Group Inc | 10.15 | 4.32 | |
13G | State Street Corp | 4.80 | -4.99 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
332,958 | 1,147,274 | 29.02 | |
210,692 | 713,067 | 29.55 | |
175,559 | 718,385 | 24.44 | |
202,506 | 879,330 | 23.03 | |
212,919 | 698,643 | 30.48 | |
(click for more detail) |
Similar Companies | |
---|---|
MRSN – Mersana Therapeutics, Inc. | MRVI – Maravai LifeSciences Holdings, Inc. |
MYGN – Myriad Genetics, Inc. | NEOG – Neogen Corporation |
NKTX – Nkarta, Inc. |
Financial data and stock pages provided by
Fintel.io